Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × nimotuzumab × Head & Neck × Clear all

Phase

Phase 2 21 Phase 3 9 Phase 4 2 Phase NA 1 Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5 Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 17 Radiotherapy 8 pembrolizumab 7 Radiotherapy, Intensity-Modulated 7 Fluorouracil 7 Magnetic Resonance Spectroscopy 6 Docetaxel 6 Platinum 5 Gemcitabine 5 1,2-diaminocyclohexaneplatinum II citrate 5 Paclitaxel 4 Specimen Handling 3 Radiation 3 Drug Therapy 3 Cetuximab 3 Carboplatin 3 (225)Ac-DOTA-c(RGDyK) 3 atezolizumab 2 Iodine-123 2 Immunoglobulin G 2 Fluorodeoxyglucose F18 2 Disulfides 2 Biopsy 2 trametinib 1 toripalimab 1 ponatinib 1 pertuzumab 1 nimotuzumab 1 fosbretabulin 1 fluorocholine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07535567 2026-04-17

NimoBenSeq

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 2/3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon ⚡